Infusion of Zoledronic Acid induces bone loss in men with hormone-naive prostate carcinoma
July 12th, 2009 Posted in hormone therapyAndrogen-deprivation therapy (ADT) decreases bone mineral density (BMD) and increases fracture risk in patients with prostate carcinoma. A research team at Kitasato University School of Medicine, Kanagawa, Japan has recently investigated the effectiveness of a single infusion of zoledronic acid initiated subsequent to ADT on BMD with hormone-naive prostate carcinoma.
According to study conclusion, bone loss begins at 6 months with ADT. A single infusion of zoledronic acid in patients receiving ADT reduces bone mineral loss and maintains BMD at least at 12 months during ADT. Further study is needed to determine the best dosing schedule to prevent ADT-induced bone loss in men with hormone-naive prostate carcinoma.